Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 4/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 8/20 | 0.36 |
| ▸ | LCAT | P04180 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5935000 | 0.81 | TACR1 (0.39) | TACR1NOTUMALDH1A1HPGD | |
| SCHEMBL5820443 | 0.78 | TACR1 (0.36) | TACR1NOTUMALDH1A1HPGD | |
| SCHEMBL324088 | 0.75 | ALDH1A1 (0.45) | GRM2PTGESNOTUMALDH1A1LMNA | |
| SCHEMBL323908 | 0.75 | NOTUM (0.41) | GRM2PTGESCHRM4NOTUMLMNA | |
| SCHEMBL13629596 | 0.71 | TACR1 (0.46) | TACR1NOTUMALDH1A1HPGD | |
| SCHEMBL8176205 | 0.70 | TACR1 (0.48) | TACR1ALDH1A1HPGD | |
| SCHEMBL8530555 | 0.70 | TACR1 (0.46) | TACR1ALDH1A1HPGD | |
| SCHEMBL325636 | 0.69 | CHRM2 (0.37) | PTGESCHRM4LMNACHRM2CHRM1 | |
| SCHEMBL13630147 | 0.69 | TACR1 (0.46) | TACR1NOTUMALDH1A1HPGD | |
| SCHEMBL13629600 | 0.68 | LMNA (0.45) | TACR1NOTUMALDH1A1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006115286-A1 | PIPERIDINE DERIVATIVES, CRYSTAL, PROCESS FOR PRODUCING THE SAME, AND USE AS TACHIKININ RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-02 | — | — | WO | disclosed |
| US-20060241145-A1 | Piperidine derivative crystal, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241145-A1 | Piperidine derivative crystal, process for producing the same, and use | PKD2, PKD1, TACR1 | GRM2 1030/4885PTGES 733/4885TACR1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.